The role of data mining in pharmacovigilance

Expert Opinion on Drug Safety

Volumn 4, Issue 5, 2005, Pages 929-948

  Hauben, Manfred ^a,b,c   Madigan, David ^d   Gerrits, Charles M ^e   Walsh, Louisa ^f   Van Puijenbroek, Eugene P ^g  

^a PFIZER INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e TAKEDA PHARMACEUTICALS   (United States)

^f ASTRAZENECA   (United Kingdom)

^g NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

Author keywords

Data mining; Disproportionality; Drug safety; Pharmacovigilance

Indexed keywords

CAPTOPRIL; CLOZAPINE; DICLOFENAC; DIGOXIN; DIURETIC AGENT; FLUOXETINE; IBUPROFEN; NAPROXEN; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PRACTOLOL; RAPACURONIUM BROMIDE; SEROTONIN UPTAKE INHIBITOR; TERFENADINE;

ALGORITHM; ANAPHYLAXIS; BAYES THEOREM; BRONCHOSPASM; COMPUTER ANALYSIS; COUGHING; DATA BASE; DISEASE SEVERITY; DRUG INDUSTRY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FREQUENCY ANALYSIS; HEADACHE; HEART ARRHYTHMIA; HUMAN; INFORMATION PROCESSING; LIVER INJURY; MEDICAL RESEARCH; MULTIPLE REGRESSION; MYOCARDITIS; NAUSEA; NEURITIS; PERITONITIS; PUBLIC HEALTH; RASH; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIGNAL DETECTION; VALIDATION PROCESS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATABASES, FACTUAL; HUMANS; INFORMATION STORAGE AND RETRIEVAL; POPULATION SURVEILLANCE; PUBLIC HEALTH;

EID: 24344432126     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.5.929     Document Type: Review

References (78)

1. MEYBOOM RH, EGBERTS AC, EDWARDS IR et al.: Principles of signal detection in pharmacovigilance. Drug Saf. (1997) 16(6):355-365.
2. HAND D, BLUNT G, KELLY M, ADAMS N: Data mining for fun and profit. Stat. Science (2000) 15(2):111-131.
3. GOODWIN L, VANDYNE M, LIN S, TALBERT S: Data mining issues and opportunities for building nursing knowledge. J. Biomed. Inform. (2003) 36(4-5):379-388.
4. LI X, RAO S, WANG Y, GONG B: Gene mining: a novel and powerful ensemble decision approach to hunting for disease genes using microarray expression profiling. Nucleic Acids Res. (2004) 32(9):2685-2694.
5. PERNER P: Image mining: issues, framework, a generic tool and its application to medical image diagnosis. Journal Engineering applications of artificial intelligence (2002) 15(3):193-203.
6. HAUBEN M, REICH J: Communication of findings in pharmacovigilance: use of term 'signal' and the need for precision in its use. Eur. J. Clin. Pharmacol. (2005) 61(5-6):479-480.
7. BATEMAN DN, SANDERS GL, RAWLINS MD: Attitudes to adverse drug reaction reporting in the Northern Region. Br. J. Clin. Pharmacol. (1992) 34(5):421-426.
8. BELTON KJ: Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur. J Clin. Pharmacol. (1997) 52(6):423-427.
9. BELTON KJ, LEWIS SC, PAYNE S, RAWLINS MD, WOOD SM: Artitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br. J Clin. Pharmacol. (1995) 39(3):223-226.
10. COSENTINO M, LEONI O, BANFI F, LECCHINI S, FRIGO G: Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Pharmacol. Res. (1997) 35(2):85-88.
11. DE BRUIN ML, VAN PUIJENBROEK EP, EGBERTS AC, HOES AW, LEUFKENS HG: Non-sedating antihistamine drugs and cardiac arrhythmias - biased risk estimates from spontaneous reporting systems? Br. J. Clin. Pharmacol. (2002) 53(4):370-374.
12. ELAND IA, BELTON KJ, VAN GROOTHEEST AC et al.: Attitudinal survey of voluntary reporting of adverse drug reactions. Br. J. Clin. Pharmacol. (1999) 48(4):623-627.
13. WILLIAMS D, FEELY J: Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir. J. Med. Sci. (1999) 168(4):257-261.
14. BEGAUD B, MORIDE Y, TUBERT-BITTER P, CHASLERIE A, HARAMBURU F: False-positives in spontaneous reporting: should we worry about them? Br. J. Clin. Pharmacol. (1994) 38(5):401-404.
15. TRONTELL A: Expecting the unexpected-drug safety, pharmacovigilance, and the prepared mind. N. Engl. J. Med. (2004) 351(14):1385-1387.
16. BATE A, LINDQUIST M, EDWARDS IR et al.: A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. (1998) 54(4):315-321.
17. EGBERTS AC, MEYBOOM RH, VAN PUIJENBROEK EP: Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf. (2002) 25(6):453-458.
18. EVANS SJ, WALLER PC, DAVIS S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. (2001) 10(6):483-486.
19. FRAM D, ALMENOFF J, DUMOUCHEL W: Empirical Bayesian data mining for discovering patterns in postmarketing drug safety. (9th ACM SlGKDD International Conference on Knowledge Discovery and Data Mining, August 24-27, 2003, Washington), (2003) p359-368.
20. HAUBEN M: A brief primer on automated signal detection Quantitative methods in pharmacovigilance: focus on signal detection. Ann. Pharmacother. (2003) 37(7-8):1117-1123.
21. SZARFMAN A, MACHADO SG, O'NEILL RT: Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. (2002) 25(6):381-392.
22. HAUBEN M, REICH L: Safety related drug-labelling changes: findings from two data mining algorithms. Drug Saf. (2004) 27(10):735-744.
23. HAUBEN M: Trimethoprim-induced hyperkalaemia - lessons in data mining. Br. J. Clin. Pharmacol. (2004) 58(3):338-339.
24. MADIGAN D: Discussion of 'Bayesian data mining in large frequency tables' by Bill DuMouchel. Am. Stat. (1999) 53:198-200.
25. DUMOUCHEL W: Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. (1999) 53(3):170-190.
26. MOSELEY J, HEELEY E, EKINS-DAUKES S, EVANS S: Preliminary comparison of 2 signal detection methodologies in the UK regulatory spontaneous ADR data base. [Abstract]. Drug Saf. (2004) 27(12):950-951.
27. VAN PUIJENBROEK EP, EGBERTS AC, HEERDINK ER, LEUFKENS HG: Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. (2000) 56(9-10):733-738.
28. VAN PUIJENBROEK EP, EGBERTS AC, MEYBOOM RH, LEUFKENS HG: Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br. J. Clin. Pharmacol. (1999) 47(6):689-693.
29. VAN PUIJENBROEK EP, EGBERTS AC, MEYBOOM RH, LEUFKENS HG: Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome? Pharmacoepidemiol. Drug Saf. (2001) 10(2):135-142.
30. NEYMAN J: On the application of probability theory to agricultural experiments. Essay on principles. Section 9, translated in Statistical Science, (with discussion). Stat. Science (1990) 5(4):465-480.
31. RUBIN D: Causal inference using potential outcomes: design, modeling, decisions. JASA (2005) 100(469):322-331.
32. CARTWRIGHT NE: Nature's Capacities and Their Measurements. Cartwright N (ed.) Oxford University Press, Oxford, (1994):
33. ROSENBAUM P, RUBIN D: The central role of the propensity score in observational studies for causal effects. Biometrika (1983) 70(1):41-55.
34. CORNFIELD J, HAENSZEL W, HAMMOND EEA: Smoking and lung cancer: recent evidence and a discussion of some questions. J Natl. Cancer Inst. (1959) 22(1):173-203.
35. LINDQUIST M, STAHL M, BATE A et al.: A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. (2000) 23(6):533-542.
36. SPIGSET O, HAGG S, BATE A: Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Clin. Psychopharmacol. (2003) 18(3):157-161.
37. SANZ EJ, DE-LAS-CUEVAS C, KIURU A, BATE A, EDWARDS R: Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet (2005) 365(9458):482-487.
38. COULTER DM, BATE A, MEYBOOM RH, LINDQUIST M, EDWARDS IR: Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ (2001) 322(7296):1207-1209.
39. BATE A, LINDQUIST M, ORRE R et al.: Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur. J. Clin. Pharmacol. (2002) 58(7):483-490.
40. VAN PUIJENBROEK EP, EGBERTS AC, MEYBOOM RH, LEUFKENS HG: Different risks for NSAID-induced anaphylaxis. Ann. Pharmacother. (2002) 36(1):24-29.
41. VAN PUIJENBROEK EP, BATE A, LEUFKENS HG et al.: A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. (2002) 11(1):3-10.
42. O'NEILL RT, SZARFMAN A: Some US Food and Drug Administration perspectives on data mining for pediatric safety assessment. Curr. Ther. Res. (2001) 62(9):650-663.
43. SZARFMAN A, TONNING JM, DORAISWAMY PM, MACHADO SG, O'NEILL RT: Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy (2004) 24(9):1099-1104.
44. BANKS D, WOO E, BURWEN D et al.: Comparing data mining methods on the VAERS database. Pharmacoepidemiol. Drug. Saf. (2005) Published Online: 13 Jun 2005
45. PURCELL P, BARTY S: Statistical techniques for signal generation: the Australian experience. Drug Saf. (2002) 25(6):415-421.
46. GOULD AL: Practical pharmacovigilance analysis strategies. Pharmacoepidemiol. Drug Saf. (2003) 12(7):559-574.
47. HAUBEN M, REICH L: Drug-induced pancreatitis: lessons in data mining. Br. J. Clin. Pharmacol. (2004) 58(5):560-562.
48. HAUBEN M, REICH L: A case report of rhabdomyolysis with pentamidine that prompted a retrospective evaluation of a pharmacovigilance tool under investigation. Br. J. Clin. Pharmacol. (2004) 58(6):675-676.
49. HAUBEN M, REICH L: Data mining, drug safety, and molecular pharmacology: potential for collaboration. Ann. Pharmacother. (2004) 38(12):2174-2175.
50. HAUBEN M, REICH L: Valproate-induced parkinsonism: use of a newer pharmacovigilance tool to investigate the reporting of an unanticipated adverse event with an 'old' drug. Mov. Disord. (2005) 20(3):387-388.
51. HAUBEN M, REICH L: Case reports of dobutamine-induced myoclonia in severe renal failure: potential of emerging pharmacovigilance technologies. Nephrol. Dial. Transplant. (2005) 20(2):471-472.
52. HAUBEN M, REICH L: Endotoxin-like reactions with intravenous gentamicin: results from pharmacovigilance tools under investigation. Infect. Control Hosp. Epidemiol. (2005) 26(4):391-394.
53. HAUBEN M, REICH L, CHUNG S: Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. Eur. J. Clin. Pharmacol. (2004) 60(10):747-750.
54. HAUBEN M, REICH L: Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: A retrospective evaluation. J. Clin. Pharmacol. (2005) 45(4):378-384.
55. HAUBEN M: Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics. Pharmacother. (2004) 24(9):1122-1129.
56. HAUBEN M: Early postmarketing drug safety surveillance: data mining points to consider. Ann. Pharmacother. (2004) 38(10):1625-1630.
57. ALMENOFF JS, DUMOUCHEL W, KINDMAN LA, YANG X, FRAM D: Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol. Drug Saf. (2003) 12(6):517-521.
58. ALMENOFF J, DUMOUCHEL W, KINDMAN L, YANG X, FRAM D: Letter to the Editor-Re: Almenoff et al., 'Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting'. Pharmacoepidemiol. Drug Saf. (2004) 13(3):111.
59. ROUX ET-B, P., THESSARD F, FOURRIER A,BEGAUD A,EVANS S.: Automatic signal detection methods evaluation on a simulated data base. Workshop 20th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Bordeaux, France, 2004.
60. ROUX E, TUBERT-BITTER P, THIESSARD F: Evaluation of data mining methods in pharmacovigilance using simulated datasets. 20th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Bordeaux, France, 2004.
61. KUBOTA K, KOIDE D, HIRAI T: Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol. Drug Saf. (2004) 13(6):387-394.
62. DE BRUIN ML, PETTERSSON M, MEYBOOM RH, HOES AW, LEUFKENS HG: Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. (2005) 26(6):590-597.
63. HARVEY JT, TURVILLE C, BARTY SM: Data mining of Australian adverse drug reactions database: a comparison of Bayesian and other statistical indicators. Intl. Tran. Op. Research (2004) 11:419-433.
64. HAUBEN M, PATADIA V, GERRITS C, WALSH L, REICH L: Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf. (2005) 28(in Press).
65. STAHL M, LINDQUIST M, EDWARDS IR et al.: Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol. Drug Saf. (2004) 13(6):355-363.
66. FINNEY DJ: The detection of adverse reactions to therapeutic drugs. Stat. Med. (1982) 1(2):153-161.
67. NOREN G, ORRE R, BATE A: A hit-miss model for duplicate detection in the WHO drug safety database. Proceedings of the 11th ACM SIGKDD international conference on knowledge discovery and data mining, August 2005, Chicago, USA.
68. GOGOLAK VV: The effect of backgrounds in safety analysis: the impact of comparison cases on what you see. Pharmacoepidemiol. Drug Saf. (2003) 12(3):249-252.
69. ALTUNDAG O, CELIK I, KARS A: Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann. Pharmacother. (2001) 35(5):641-642.
70. YEE C, KLINCEWICS S, KNIGHT J, THOMAS A, WILSON R: Practical consideration in developing an automated signaling program within a pharmacovigilance department. Drug Inf. J. (2004) 38(3):293.
71. HAUBEN M, REICH L: Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics. Pharmacother. (2004) 24(9):1122-1129.
72. PURCELL PM: Data mining in pharmacovigilance Int. J. Pharm. Med. (2003) 17(2):63-64.
73. BROWN EG: Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf. (2002) 25(6):445-452.
74. BROWN EG: Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. (2003) 26(3):145-158.
75. BROWN EG: Using MedDRA: implications for risk management. Drug Saf. (2004) 27(8):591-602.
76. HAND D: Technical report, Department of Mathematics, Imperial College London.
77. STROM BL: Evaluation of suspected adverse drug reactions. JAMA (2005) 293(11):1324-1325.
78. ALMENOFF JS, DUMOUCHEL W, KINDMAN LA et al.: Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol. Drug Saf. (2003) 12(6):517-521.